Why the study?
Does heparin infusion or oral anticoagulation reduce mortality and thromboembolic complications in patients with pulmonary thromboembolism compared to supportive therapy?
Does heparin infusion or oral anticoagulation reduce mortality and thromboembolic complications in patients with pulmonary thromboembolism compared to supportive therapy?
Prolonged continuous heparin infusion significantly reduces both thromboembolic morbidity and mortality in patients with pulmonary thromboembolism.
Answers are grounded in this paper and cite their sources.
Supports heparin consideration in pulmonary thromboembolism; observational data leave open need for randomized confirmation before practice change.
Summary A retrospective survey of patients admitted to hospital with pulmonary thromboembolism during 1971 is reported, and the methods of treatment commonly used are compared. The outcome in these patients was also compared with those receiving supportive therapy. The use of oral anticoagulants with or without the addition of heparin for the first 72 hours resulted in a significant reduction in mortality by decreasing the incidence of further fatal thromboembolism. These regimens did not significantly decrease the total number of further thromboembolic complications. Treatment with prolonged infusion of heparin without oral anticoagulants resulted in a significant reduction of both thromboembolic morbidity and mortality. Despite the difficulties of valid comparisons between methods of treatment of pulmonary thromboembolism, it is concluded that the superiority of continuous heparin infusion justifies the need for a prospective assessment of the optimum length of treatment with heparin infusion.
No takes yet. Share an insight, caveat, or question.
John А. Kanis (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: